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Background: In recent years different IRT/PAP protocols have been evaluated, but the individual performance remains unclear. To optimize the
IRT/PAP strategy we compared protocols from three regional CF newborn screening centers (Heidelberg, Dresden, and Prague).
Methods: We evaluated the effect of elevating the IRT-cut-off from 50 to 65 μg/l (~97.5th to ~99.0th percentile), the need of a failsafe protocol
(FS, IRT ≥ 99.9th percentile) and the relative performance using either two IRT-dependent PAP-cut-offs or one PAP-cut-off.
Findings: Elevation of the IRT cut-off to 65 μg/l (~99.0th percentile) increased the PPV signiﬁcantly (Dresden: 0.065 vs. 0.080, p b 0.0001,
Prague: 0.052 vs. 0.074, p b 0.0001) without reducing sensitivity. All three IRT/PAP protocols showed a trend towards a higher sensitivity with
FS than without and when using one PAP-cut-off instead of two IRT-dependent PAP-cut-offs.
Conclusions: For best performance we suggest an IRT/PAP protocol with an IRT-cut-off close to the 99.0th percentile, FS, and a single PAP-cut-off.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Newborn screening; Biochemical screening; Pancreatitis associated protein; Immunoreactive trypsinogenAbbreviations: CF, cystic fibrosis; CFNBS, cystic fibrosis newborn screening; DBS, dried blot spot; FS, failsafe strategy; IRT, immunoreactive trypsinogen; NBS,
newborn screening; MI, meconium ileus; PAP, pancreatitis associated protein; PS, pancreatic sufficient; PI, pancreatic insufficient
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Agreement on the benefits of newborn screening (NBS) for
cystic fibrosis (CF) [1] led to widespread implementation of CF
screening programs [2,3]. Most protocols rely on a combination
of IRT quantitation and genetic analysis [4], with a CFTR
mutation panel adapted to the respective population. Since
previous studies demonstrated that IRT/DNA protocols achieve
good sensitivity and specificity (e.g. [5]) this strategy is currently
used in most countries. However, often discussed concerns
against genetic CFNBS including detection of heterozygotes and
clinically equivocal forms, legislative and ethical issues as well as
ethnic diversity [6], led to the development of alternative bio-
chemical protocols that can bypassCFTRmutation analysis using
IRT in combination with pancreatitis associated protein (PAP) as
second tier analysis [7].
During the past years, different IRT/PAP protocols were
tested [7–10]. Beside the original protocol of Sarles et al. [7] with
two IRT-dependent cut-offs, an alternative IRT/PAP method was
evaluated at the Heidelberg CFNBS center with only one PAP
cut-off based on the assumption that two IRT-dependent PAP
cut-offs may have limitations in sensitivity [8]. Further, a third
protocol was developed in The Netherlands, in which the original1. Tier
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The present retrospective study addressed several questions
important for further optimization of the IRT/PAP screening
strategy when used as an exclusive, biochemical protocol without
genetic testing, as well as a combined testing with genetic
analysis as third tier. We used the results from three regional
CFNBS programs carried out in ethnically differing central
European populations and using varying IRT/PAP protocols
(Fig. 1). The combined evaluation of these data provided the
opportunity of a retrospective analysis of the different IRT/PAP
protocols to draw important conclusions on how to improve the
IRT/PAPmethod. Specifically, we addressed the questions 1) if it
is possible to elevate the IRT cut-off above 50.0 μg/l to achieve a
higher specificity; 2) if an IRT/PAP protocol benefits from a
failsafe strategy (FS); and 3) whether an IRT/PAP protocol with
one PAP cut-off level achieves higher sensitivity than a protocol
with two IRT-dependent PAP-cut-offs.
2. Methods
The CFNBS centers in Heidelberg, Dresden (Germany) and
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performed prospectively and were initially assessed individually
[8,10,11]. For this study the data were shared among the centers.
2.1. Population
The presented data were obtained from April 2008 to August
2011 in the NBS center Heidelberg (~44,000 newborns p.a.),
from February 2008 to December 2010 in the NBS center
Dresden (~15,000 newborns p.a.), and from August 2009 to
January 2011 in the NBS center of Prague (~70,000 newborns
p.a.). All original study protocols were approved by local ethics
committees and/or local authorities and informed consent was
provided by the parents. More information regarding the cov-
erage of the programs and the legislation of informed consent in
the different countries is given in the online supplement.
2.2. Test protocols
The methods of the individual IRT/PAP protocols used in
Heidelberg and Prague are described elsewhere [8,10]. Details
of all three IRT/PAP protocols are given in Fig. 1 and in more
detail in the online supplement. Only the main differences
between the protocols are described here.
IRT was used as first tier in all CFNBS centers (Heidelberg:
floating IRT-cut-off ≥ 99.0th percentile, ~60-70 μg/l; Dresden
and Prague: ≥50 μg/l, ~97.5th percentile, respectively). In
Dresden and Prague positive rating of PAP as second tier was
depended on two different PAP cut-offs (PAP ≥ 1.8 μg/l if IRT
50.0–99.9 μg/l, and PAP ≥ 1.0 μg/l if IRT ≥ 100 μg/l) [7]. In
Heidelberg a protocol with one PAP cut-off (IRT ≥ 99.0th
percentile, PAP ≥ 1.0 μg/l) was used [8].
In Heidelberg and Dresden, an additional failsafe strategy
(FS) was added to the IRT/PAP protocol. According to that
CFNBS was also rated positive if IRT was ≥99.9th percentile
regardless of the second tier test results (IRT/PAP-FS).
The centers in Heidelberg and Prague compared their IRT/
PAP results internally to an IRT/DNA protocol run in parallel
(Table S1 and details in online supplement). In Dresden there
was no independent assessment of the quality of the IRT/PAP
results. However, until July 2012 there were no reports of CF
patients diagnosed clinically during and after the study period
missed by the IRT/PAP-FS protocol used in Dresden.
2.3. Medical evaluation
CFNBS in the original studies was considered positive, if
IRT was elevated and either PAP testing reached the individual
cut-offs described above (Heidelberg, Dresden, Prague), one or
two CFTR mutations were identified (Heidelberg, Prague), or
IRT concentration was ≥99.9th percentile (FS for Dresden
138 μg/l, for Heidelberg floating from118 to 144 μg/l). In case
of a positive rated CFNBS, the parents of the newborn were
contacted and referred to a local CF center for sweat chloride
(Cl−) testing and clinical assessment. Sweat tests in all local CF
centers were performed according to the Gibson-Cooke Quan-
titative Pilocarpin Iontophoresis according to internationalguidelines [12,13] either with the original filter pad collection
method (Czech Republic) or with the Macroduct® collection
method (Germany). Cl− concentrations ≥ 60 mmol/l in two
independent samples were considered diagnostic of CF, Cl−
concentrations between 30 and 60 mmol/l were considered
borderline and led to an extended work up including extended
genetic testing and/or functional evaluation of CFTR-mediated
Cl− secretion using intestinal current measurements, as previ-
ously described [14–16]. In Dresden nearly all CFNBS positive
rated newborns were seen in the CF center Dresden for medical
evaluation. In Heidelberg about 10% and in Prague about 21%
[10] of the parents of CFNBS positive rated newborns refused
sweat testing and further medical evaluation.
2.4. Retrospective analysis
To address the question whether the IRT-cut-off can be
elevated to increase specificity, raw data from Dresden and
Prague were reanalyzed as if the IRT-cut-off had been either
50 μg/l (~97.5th percentile), 60 μg/l (~98.5th percentile), or
65 μg/l (~99.0th percentile). The obtained results were compared
to the original findings. Since in Heidelberg a floating IRT-
cut-off of ≥99.0th percentile (60–70 μg/l) was used from the
beginning of the study, no data obtained with lower IRT-cut-offs
were available which could be used for a similar analysis.
For the question on the necessity of an FS protocol data from
Prague were analyzed as if they would have used an FS protocol
in their IRT/PAP protocol as done in Heidelberg and Dresden.
The FS IRT-cut-off of the 99.9th percentile for Prague was
calculated to be 143 μg/l. In turn, raw data from Heidelberg and
Dresden were analyzed, as if these centers would not have used a
FS protocol, and the results were compared to those of the
original study. The results of the different scenarios were com-
pared and statistically analyzed.
To answer the question whether an IRT/PAP protocol per-
forms better with two IRT-dependent PAP cut-offs according to
Sarles et al. [7], or one PAP cut-off according to Sommerburg et
al. [8] raw data from Heidelberg were reanalyzed as if two
IRT-dependent PAP-cut-offs were used. Raw data from Dresden
and Prague were reanalyzed in two ways: First, for an optimized
protocol with two IRT-dependent PAP-cut-offs (PAP ≥ 1.8 μg/l
if IRT 60.0–99.9 μg/l, and PAP ≥ 1.0 μg/l if IRT ≥ 100 μg/l)
and second, for a protocol similar to the one used in Heidelberg
[8] with one PAP cut-off (IRT ≥ 60 μg/l, PAP ≥ 1.0 μg/l).
Thereafter, the results of both protocols were compared for each
of the three cohorts.
2.5. Statistical analysis
The data of the CFNBS cohorts were collected in a Microsoft
Access 2010 database (Heidelberg), in the newborn screening
program LD NGS (Dresden), or Microsoft Excel 2010 (Prague).
To evaluate the performance of the different protocols statistical
analysis was performed only for patients with an expected typical
course of CF disease. CF patients with meconium ileus (MI) were
not included into statistical analysis since they are expected to be
diagnosed immediately after birth. Furthermore, newborns with
18 O. Sommerburg et al. / Journal of Cystic Fibrosis 13 (2014) 15–23equivocal CF diagnosis were also excluded from statistical
analysis since they are not the target of NBS [3,17]. Performances
of the different protocols were compared using exact binomial
test. p-values of b0.05 were considered statistically significant.
Statistical analyses were performed with Microsoft Excel 2010,
and the actual free “R” software package “DTComPair” [18].
3. Results
Altogether 325,917 newborns were screened for CF in the
three CFNBS centers participating in this study. Fig. S1 in the
online supplement provides an overview over the results of the
CFNBS protocols used in the individual studies.
3.1. IRT cut-off in an IRT/PAP protocol
An increase in the IRT-cut-off from 50 μg/l (~97.5th
percentile) to either 60 μg/l (~98.5th percentile) or 65 μg/l
(~99.0th percentile) in the cohorts of Dresden and PragueTable 1
Comparison of IRT/PAP-FS protocols with two IRT-dependent PAP cut-offs differi
The data given represent the results of a retrospective analysis using raw data of the
equivocal diagnose of CF are presented in the table but were excluded from stati
protocol with an IRT-cut-off of 50 μg/l in the same cohort: ⁎p b 0.001; ⁎⁎p b 0.00
Cohort Dresden
Newborns screened 56,326
Newborns with 2
mutations in the
CFTR gene detected
during and after the
original study
10
Screening protocol
(IRT [μg/l], PAP
[μg/l])
Originally used
protocol
IRT/PAP-FS protocol
(IRT 50.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Retrospective
analysis
IRT/PAP-FS protocol
(IRT 60.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Retrospective
analysis
IRT/PAP-FS
(IRT 65.0–99
PAP ≥ 1.8 μ
IRT ≥ 100 μ
PAP ≥ 1.0 μ
Test positive (TP) 107 (0.19%) 92 (0.16%) 87 (0.15%)
Detected CF w/o MI 7 7 7
Detected CF with
MI a
1 1 1
Positive, equivocal
diagnosis a
1 1 1
False positive 100 85 80
Test negative 56,219 56,234 56,239
True negative 56,219 56,234 56,239
False negative, CF
w/o MI
0 0 0
False negative, CF
with MIa
1 1 1
Negative, equivocal
diagnosis a
0 0 0
Sensitivity, %
(95% CI)
1.000 (1.000–1.000) 1.000 (0.676–1.000) 1.000 (0.676–
Specificity, %
(95% CI)
0.9982 (0.9982–
0.9992)
0.9985⁎ (0.9985–
0.9985)
0.9986⁎⁎ (0.9
0.9986)
PPV, % (95% CI) 0.0654 (0.0186–
0.1128)
0.0761⁎⁎ (0.0219–
0.1302)
0.0804⁎⁎ (0.0
0.1376)
a These newborns were excluded from statistical analysis.resulted in a substantial decrease of false-positive tested new-
borns leading to a significant increase of specificity as well as the
positive predictive value (PPV, Table 1). The sensitivity did not
change in either of the cohorts. Up to an IRT cut-off of 65 μg/l
(~99.0th percentile), no CF patient would have been missed in
Dresden. In the cohort of Prague, up to an IRT cut-off of 60 μg/l
(~98.5th percentile), all CF patients would have been detected.
When using an IRT-cut-off of 65 μg/l (~99.0th percentile) one
CF patient withMI would have been missed in the Prague cohort,
however, this CF patient was diagnosed clinically.
3.2. Evaluation of the necessity of a failsafe protocol in an IRT/
PAP protocol
The results of the retrospective analysis of the effects of a FS
protocol are summarized in Table 2. Considering only CF patients
without MI, sensitivity of the original IRT/PAP protocol without
FS used in Prague was 74%. After reanalyzing the data for an
IRT/PAP-FS protocol, sensitivity increased to 90% (p = 0.999).ng in the IRT cut-off as first tier of the protocol: 50 μg/l, 60.0 μg/l, or 65 μg/l.
cohorts of Dresden and Prague. All CF patients with MI and all newborns with
stical calculations. Marked results are statistically significant compared to the
01.
Prague
106,522
23
protocol
.9 μg/l,
g/l/
g/l,
g/l)
Retrospective
analysis
IRT/PAP-FS protocol
(IRT 50.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Retrospective
analysis
IRT/PAP-FS protocol
(IRT 60.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Retrospective
analysis
IRT/PAP-FS protocol
(IRT 65.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
325 (0.30%) 257 (0.24%) 230 (0.22%)
17 17 17
2 2 1
1 1 1
308 240 213
106,197 106,265 106,292
106,195 106,263 106,290
2 2 2
0 0 1
1 1 1
1.000) 0.895 (0.757–1.033) 0.895 (0.757–1.033) 0.895 (0.757–1.033)
986– 0.9971 (0.9971–
0.9971)
0.9977⁎⁎ (0.9977–
0.9978)
0.9980⁎⁎ (0.9979–
0.9980)
233– 0.0523 (0.0281–
0.0765)
0.0661⁎⁎ (0.0357–
0.0965)
0.0739⁎⁎ (0.0401–
0.1077)
Table 2
Comparison of PAP-based CF NBS protocols with or without a failsafe strategy. For this analysis a FS strategy was applied using an IRT cut-off ≥ 99.9th percentile. Statistical analysis was performed only with CF
patients without meconium ileus (MI). All CF patients with MI and all newborns with equivocal diagnose of CF are presented in the table but were excluded from statistical calculations. Marked results are statistically
significant compared to the protocol without an FS strategy in the same cohort: ⁎⁎p b 0.0001.
Cohort Heidelberg Dresden Prague
Newborns screened 163,069 56,326 106,522
Newborns with 2
mutations in
the CFTR gene
detected during and
after the original study
34 10 23
Screening protocol Retrospective analysis
w/o FS
IRT/PAP (IRT ≥ 99.0
P., PAP ≥ 1.0 μg/l)
Originally used protocol
with FS
IRT/PAP-FS (IRT ≥ 99.0
P., PAP ≥ 1.0 μg/l)
Retrospective analysis w/o FS
IRT/PAP (IRT 50.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Originally used protocol with FS
IRT/PAP-FS (IRT 50.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Originally used protocol w/o FS
IRT/PAP (IRT 50.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Retrospective analysis
with FS IRT/PAP-FS
(IRT 50.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Test positive 245 (0.15%) 287 (0.18%) 99 (0.18%) 107 (0.19%) 260 (0.24%) 325 (0.31%)
Detected CF w/o MI 21 23 6 7 14 17
Detected CF with MI a 7 7 1 1 2 2
Positive, equivocal
diagnosis a
0 0 1 1 1 1
False positive 224 264 93 100 246 308
Test negative 162,824 162,782 56,227 56,219 106,262 106,197
True negative 162,820 162,780 56,226 56,219 106,257 106,195
False negative, CF
w/o MI
4 b 2 b 1 0 5 2
False negative, CF
with MI a
0 0 1 1 0 0
Negative, equivocal
diagnosis a
2 2 0 0 1 1
Sensitivity, % (95% CI) 0.840 (0.696–0.984) 0.920 (0.814–1.026) 0.857 (0.598–1.116) 1.000 (1.000–1.000) 0.737 (0.539–0.935) 0.895 (0.757–1.033)
Specificity (95% CI) 0.9986 (0.9986–0.9987) 0.9984⁎⁎ (0.9984–0.9984) 0.9983 (0.9983–0.9984) 0.9982 (0.9982–0.9982) 0.9977 (0.9976–0.9977) 0.9971⁎⁎ (0.9971–0.9971)
PPV 0.0857 (0.0507–0.1207) 0.0801 (0.0487–0.1116) 0.0606 (0.0136–0.1076) 0.0654 (0.0186–0.1122) 0.0538 (0.0264–0.0812) 0.052 (0.0281–0.0765)
a These newborns were excluded from statistical analysis.
b One of these patients was not diagnosed because of low initial IRT (36 μg/l).
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Fig. 2. Newborns with CF-related mutations in the CFTR gene detected in the
cohorts from Heidelberg and Prague by the IRT/PAP and IRT/DNA protocols
used. Summary of the performance of an IRT/PAP protocol with one PAP
cut-off of 1.0 μg/l and an IRT/PAP protocol with two IRT-dependent cut-offs
(IRT 50.0–99.9 μg/l, PAP ≥ 1.8 μg/l; IRT ≥ 100 μg/l, PAP ≥ 1.0 μg/l).
Abbreviations: HD — Heidelberg, PR — Prague.
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IRT/PAP protocol [10] would have been identified, if a FS had
been applied. The retrospective analysis performed with raw data
fromHeidelberg andDresden confirmed that sensitivity calculated
for detected CF patients drops from 92% to 84% (p = 0.999) and
from 100% to 86% (p = 0.999), respectively, if an IRT/PAP
protocol without FS is used. None of these results reached
statistical significance; however, there was a general trend towards
a higher sensitivity, when a FS protocol was used. Apart from that
using a FS protocol led to a slightly lower specificity. These
changes were statistically significant (p b 0.0001) for the cohorts
of Heidelberg and Prague, respectively.3.3. Performance of IRT/PAP protocols using either two IRT-
dependent PAP-cut-offs or one PAP cut-off
IRT and PAP values of all newborns with two CFTR
mutations diagnosed in Heidelberg and Prague with respect to
the PAP cut-off levels of the individual IRT/PAP protocols are
shown in Fig. 2. If an IRT/PAP-FS protocol with two IRT-
dependent PAP cut-offs had been used in the centers of
Heidelberg and Prague eight newborns with two CFTR mu-
tations had not been detected. Three out of these had normal
sweat tests (HD-10, HD-13, PR-19) and were considered as
newborns with equivocal CF diagnosis. Two out of the
remaining five had MI (HD-15, HD-18) and were diagnosed
clinically after birth. The remaining three newborns missed had
CF (HD-29, PR-16, PR-21). In contrast, if an IRT/PAP-FS
protocol with one PAP cut-off [8] had been applied only four
newborns with two CFTR mutations had not been found. Two
out of these had a normal sweat chloride (HD-15, HD-18), but
the remaining two (HD-29, PR-16) had CF. To follow
individual newborns, we refer to the Tables S2, S3, and S4 in
the online supplement providing an overview over all newbornswith two CFTR mutations diagnosed in the three CFNBS
centers.
Table 3 shows the results of the retrospective analysis of both
an optimized IRT/PAP-FS protocol with two IRT-dependent PAP
cut-offs and of the IRT/PAP-FS protocol with one PAP cut-off. In
the cohorts of Heidelberg andDresden, no differences in sensitivity
is seen using either of the protocols. However, in the cohort of
Prague, one CF patient was missed with the IRT/PAP-FS protocol
with two IRT-dependent PAP-cut-offs, but was found with the
protocol with one PAP-cut-off. This led to a trend towards higher
sensitivity in favor of the latter protocol (90% vs. 95%), but this
change was statistically not significant (p = 0.999). In all three
cohorts, the number of false positives was higher when using one
PAP cut-off resulting in a significant decrease of specificity and of
positive predictive value (Table 3).
4. Discussion
By evaluating three different IRT/PAP protocols, this study
addressed several important questions relevant for further
improvement of a PAP based CFNBS.
First, we asked whether the IRT cut-off concentration for a
PAP based CFNBS protocol can be elevated. While the original
IRT/PAP method suggested an IRT cut-off of 50 μg/l (~97.5th
percentile) [7], the protocol run in Heidelberg relied on an IRT
cut-off ≥ 99.0th percentile (floating from 60 to 70 μg/l) similar
to that often used in IRT/DNA protocols [8]. The reason for
using the low cut-off of 50 μg/l (~97.5th percentile) in the
original IRT/PAP protocol [7] was the fear of an inadequate
sensitivity when IRT and PAP are used simultaneously as
combined parameters. However, in all PAP based protocols
applied nowadays, IRT and PAP are measured sequentially.
Thus, considering IRT as first tier test, the situation is similar to
an IRT/DNA protocol. Along these lines, the IRT cut-off was
already increased to 60 μg/l (~98.5th percentile) when the IRT/
PAP-FS/DNA protocol was implemented in The Netherlands
[9]. Our results based on recalculations of the data obtained in
Dresden and Prague show that an IRT cut-off of 65 μg/l
(~99.0th percentile) can be used without reducing sensitivity.
In turn, increasing the IRT cut-off in IRT/PAP protocols
reduces significantly the number of PAP measurements and the
rate of false positives. This results in a significant increase in
specificity and in the PPV as shown for both the cohorts from
Dresden and Prague (Table 1).
Second, we addressed the question whether the use of a FS is
required as it is known for IRT/DNA based protocols [19,20].
One possibility for a FS is to request a second dry blood spot after
day 21 for a repeated IRT measurement [3]. However, recalling
newborns with unclear CFNBS results for a second heel prick is
not feasible everywhere and therefore a number of IRT/PAP
protocols, e.g. in Germany or in The Netherlands, were combined
with a FS executed when IRT ≥ 99.9th percentile regardless of
the second tier test result [8,9]. From the three IRT/PAP protocols
compared in this paper, only the one run in Prague was without
FS [10] and it could be shown that three of the five newborns
missed in the original study by IRT/PAP would have been
detected with FS (Table 2). Similar results were obtained when
Table 3
Retrospective analysis using the raw data of the cohorts of Heidelberg, Dresden, and Prague: Comparison of an optimized IRT/PAP-FS protocol with two
IRT-dependent PAP cut-offs (PAP ≥ 1.8 μg/l, if IRT 60.0–99.9 μg/l and PAP ≥ 1.0 μg/l, if IRT ≥ 100 μg/l) with an IRT/PAP-FS protocol with one PAP cut-off
(IRT ≥ 99.0 percentile for Heidelberg/IRT ≥ 60 μg/l for Dresden and Prague, PAP ≥ 1.0 μg/l). All CF patients with MI and all newborns with equivocal diagnose
of CF are presented in the table but were excluded from statistical calculations. Marked results are statistically significant compared to the respective protocol with
two IRT-dependent PAP-cut-offs in the same cohort: ⁎⁎p b 0.0001.
Cohort Heidelberg Dresden Prague
Newborns
screened
163,069 56,326 106,522
Newborns with
2 mutations in
the CFTR gene
34 10 23
Prevalence of
newborns with
2 mutations in
the CFTR gene
1:4796 (3432–6701) 1:5633 (3060–10,369) 1:4631 (3087–6950)
Screening
protocol
Retrospective analysis
IRT/PAP-FS a protocol
(IRT 60.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Originally used
protocol
Heidelberg
protocol of IRT/
PAP-FS
(IRT ≥ 99.0 P.,
PAP ≥ 1.0 μg/l)
Retrospective analysis
IRT/PAP-FS protocol
(IRT 60.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Retrospective
analysis
Heidelberg
protocol of IRT/
PAP-FS
(IRT ≥ 99.0 P.,
PAP ≥ 1.0 μg/l)
Retrospective analysis
IRT/PAP-FS protocol
(IRT 60.0–99.9 μg/l,
PAP ≥ 1.8 μg/l/
IRT ≥ 100 μg/l,
PAP ≥ 1.0 μg/l)
Retrospective
analysis
Heidelberg
protocol of IRT/
PAP-FS
(IRT ≥ 99.0 P.,
PAP ≥ 1.0 μg/l)
Test positive (TP) 174 (0.11%) 287 (0.18%) 92 (0.16%) 122 (0.22%) 257 (0.24%) 390 (0.37%)
Detected CF
w/o MI
23 23 7 7 17 18
Detected CF
with MI b
5 7 1 1 2 1
Positive,
equivocal
diagnosis b
0 0 1 1 1 2
False positive 151 214 85 115 240 372
Test negative 162,895 162,782 56,234 56,204 106,265 106,132
True negative 162,893 162,780 56,234 56,204 106,263 106,131
False negative,
CF w/o MI
2 c 2 c 0 0 2 1
False negative,
CF with MI b
2 0 1 1 0 1
Negative,
equivocal
diagnosis b
2 2 0 0 1 0
Sensitivity, %
(95% CI)
0.920 (0.814–1.026) 0.920 (0.814–1.026) 1.000 (0.676–1.000) 1.000 (1.000–1.000) 0.895 (0.757–1.033) 0.947 (0.847–
1.048)
Specificity, %
(95% CI)
0.9991 (0.9991–0.9991) 0.9984⁎⁎ (0.9984–
0.9984)
0.9985 (0.9985–0.9985) 0.9980⁎⁎ (0.9980–
0.9980)
0.9977 (0.9977–0.9978) 0.9965⁎⁎ (0.9965–
0.9965)
PPV, %
(95% CI)
0.1322 (0.0819–0.1825) 0.0801⁎⁎ (0.0487–
0.1116)
0.0761 (0.0219–0.1302) 0.0573⁎⁎ (0.0161–
0.0986)
0.0661 (0.0357–0.0965) 0.0437⁎⁎ (0.0233–
0.0640)
a The IRT/PAP-FS protocol with two IRT-dependent PAP cut-offs for the cohort of Heidelberg could be simulated only with the data available. In the original study in
Heidelberg the IRT cut-off was set to ≥99.0th IRT percentile (~60–70 μg/l). This leads here to a smaller number of IRT positives compared to the other cohorts.
b These patients were not included into statistical calculations.
c One of these patients was not diagnosed because of an initially low IRT (36 μg/l).
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reanalyzed (Table 2). Due to the limited number of newborns in
the individual substudies, the changes in sensitivity did not reach
statistical significance. However, the trend towards an increased
sensitivity when using FS could be seen in all three cohorts. Our
results indicate that the use of a FS, e.g. rating of all newborns
with negative PAP but an IRT ≥ 99.9th percentile as a positive
test result, may improve sensitivity.
Third, we determined the effect of different PAP cut-off levels
on the performance of PAP based CFNBS. To our knowledge, allcurrently used IRT/PAP protocols (e.g. [7,9]), except in Heidelberg
[8], rely on two IRT-dependent PAP cut-offs. The reason to use
two PAP cut-offs was based on the assumption that in the IRT
range of 50.0 to 99.9 μg/l, lower PAP values may reflect mild CF
phenotypes, which should not be detected. When the IRT/PAP
strategywas implemented inHeidelberg, it was decided to use only
a single PAP cut-off level of ≥1.0 μg/l, because there is no
evidence so far that PAP concentration generally correlates with
CF disease severity. This notion is also supported by our present
data showing higher PAP levels in some patients with PS
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patients with PI mutations (i.e. F508del). Fig. 2 shows all
newborns with IRT ≥ 50 μg/l and two CF related mutations
detected in the cohorts of Heidelberg and Prague. Comparing the
different IRT/PAP protocols, four newborns with two mutations in
the CFTR gene (HD-15, HD-18, PR-19, and PR-21 in Tables S2
and S4 in the online material) would have been missed by the IRT/
PAP protocol with two IRT dependent PAP cut-offs, but would
have been detected by the protocol with one PAP cut-off. Only one
out of these four newborns missed carried one “mild” mutation in
the CFTR gene and had a normal sweat chloride (PR-19). The
other three newborns were diagnosed with CF. Two out of these
three CF patients suffered from MI (HD-15, HD-18) and would
have been diagnosed clinically. However, the third CF patient
(PR-21) would have been missed by all IRT/PAP protocols relying
on two IRT-dependent PAP cut-offs (e.g. [7,9,10]). It can be
argued whether we have to consider three missed patients with CF
or only one since two out of these three presented withMI. The fact
that newborns carrying two CF causing mutations were not
detected due to the IRT/PAP-FS protocol with two PAP cut-offs,
raises the question whether this protocol is reliable enough for
CFNBS. The comparison of the results of the different IRT/
PAP-FS protocols (Table 3) suggests the use of only one PAP
cut-off which showed a trend towards a higher sensitivity in the
cohort of Prague, but led also to a higher false positive rate and to a
lower specificity. Nevertheless, our results support a protocol with
only one PAP cut-off until a well-powered study is available
clearing this issue. During the introduction of an IRT/PAP protocol
for CFNBS, the disadvantage of a higher false positive rate of a
protocol with one PAP-cut-off will be offset by its expected higher
sensitivity. Furthermore, combining this protocol with genetic
testing as third tier will keep the higher sensitivity, but eliminate
the disadvantage of the higher false positive rate.
Our study has several limitations which need to be considered
in the interpretation of the results. First, two newborns without
MI carrying CF causing mutations (HD-29, PR-16 in Tables S2
and S4 in the online material) were missed by both of the IRT/
PAP protocols since PAP values of these newborns were lower
than 1.0 μg/l. One of these two CF patients (HD-29) was born
preterm in the 30th week of gestation and a second Guthrie card
was not tested later for CF as usually done for other diseases
included in NBS. Of note, Vernooij-van Langen et al. demonstrat-
ed that PAP values of preterm infants are variable [21]. This
suggests that false negative PAP results might be explained by low
PAP values in preterm infants, and that retesting of those close to
the calculated birth datemay bewarranted when using an IRT/PAP
protocol. Alternatively, the low PAP in this patient (HD-29) might
be explained by expression of R347P mutation which is partially
associated with exocrine pancreatic sufficiency and might there-
fore result in a lower PAP value after birth. Up to now there is no
explanation why the second CF patient (PR-16) could not be
detected by either of the PAP based CFNBS protocols. During the
original study carried out in Prague all false negative results were
verified by PAP re-examination and discussed directly with the
manufacturer of the PAP kit. In this process no analytical or
handling error was revealed. Another false negative tested CF
patient (HD-01) not given in Fig. 2 was missed because of an IRTvalue far below the cut-off (36 μg/l). Nonetheless, this patient
would have beenmissed by any other IRT based screening strategy
and should, therefore, not considered as false negative result
specific for PAP based CFNBS protocols. Nevertheless, it might
happen that more individual patients are missed due to mobility of
families, although Germany and the Czech Republic have reliable
CF networks reporting CF patients tested false-negative by
CFNBS to the NBS center.
Second, none of the study cohorts was large enough and was
followed long enough to calculate sensitivity reliably. Further-
more, exclusion of CF patients with MI and of newborns with
equivocal CF diagnosis from statistical analyses puts the focus
on the relevant patients for a NBS study, but weakens deter-
mination of protocol sensitivity even further. This is the main
reason why sensitivities reported here are lower than in other
IRT/PAP studies [7–10]. Of note, if positive rated newborns
who presented with MI after birth and were diagnosed with
CF had been included in the statistical analysis, the sensitivity
e.g. in the Heidelberg cohort would have increased from 92%
up to 95%.
Third, in Heidelberg about 10% and in Prague about 21%
[10] of the parents whose newborns were tested positive in the
CFNBS refused confirmation of the test result by sweat testing
and/or further clinical evaluation despite of respective efficient
tracking procedures. This is an important fact since this could
have influenced the initial results of these two cohorts and has
to be taken into consideration when interpreting the results of
this retrospective study.
Finally, differences between the calculated sensitivities of the
studied protocols were too small to reach statistical significance
for the given sizes of our cohorts. A power calculation predicted
that a difference of 8 newborns would have been necessary to
reach statistical significance between the calculated sensitivities
of the different protocols compared in our retrospective study.
Therefore, we expect that ≥800,000 newborns have to be
screened to demonstrate significant differences in sensitivities
between screening protocols by comparative statistical analysis.
However, we think these limitations do not impair the relevance
or the findings reported in this study.
In summary, our results support that an IRT/PAP protocol is
a good choice, if genetic analysis has to be avoided or if
detection of carriers and newborns with equivocal diagnosis of
CF should be limited. To optimize the specificity of an IRT/
PAP protocol an IRT cut-off close to the 99.0th percentile
(~65 μg/l) can be applied. Usage of a FS in an IRT/PAP
protocol may improve sensitivity and usage of only one PAP
cut-off may further increase the sensitivity, but lower the
specificity when IRT/PAP is used as exclusive biochemical
strategy.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2013.06.003.
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